Overview
Title
An Act To extend the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health, and for other purposes.
ELI5 AI
This bill wants to keep giving money to help doctors and scientists study and find better ways to treat children who are sick, making sure they work together and don't do the same work twice.
Summary AI
H.R. 3391, also known as the "Gabriella Miller Kids First Research Act 2.0," aims to extend funding for pediatric research initiatives at the National Institutes of Health (NIH) through 2028. The bill modifies existing laws to ensure funds are allocated to the Division of Program Coordination, Planning, and Strategic Initiatives and emphasizes avoiding duplication of research efforts. It also underscores the importance of coordinated pediatric research and requires a report in five years on the progress and investments made in pediatric research.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary
The legislative piece under discussion, titled the "Gabriella Miller Kids First Research Act 2.0," aims to extend and refine an existing pediatric research program at the National Institutes of Health (NIH). The bill seeks to ensure a continued focus on pediatric research initiatives through strategic funding and oversight adjustments. It was recently received and reviewed by the Senate, and primarily focuses on reallocating funds towards pediatric research from 2024 to 2028 while also emphasizing coordination and reducing duplication in research efforts.
Summary of Significant Issues
One of the key issues within the bill is the lack of detail regarding how the funds for the Pediatric Research Initiative will be specifically allocated. This might result in potential oversight issues and lapse in transparency or accountability. Furthermore, the bill doesn't clearly explain the implications of shifting the management of funds from the "Common Fund" to the "Division of Program Coordination, Planning, and Strategic Initiatives." This change could lead to concerns about continuity and effectiveness of initiatives previously supported.
Another important issue arises from the amendments concerning the coordination of NIH funding for pediatric research, where no specific criteria or mechanisms for avoiding duplication in research are mentioned. This could potentially lead to overlapping funding for similar projects and inefficient use of resources. Additionally, striking the term "10-year" from the legislation text might cause confusion regarding the duration of the funding period.
In the section regarding reporting progress in pediatric research, the lack of defined criteria for evaluating what constitutes advancements could lead to subjective and potentially misleading reports. This absence of clarity affects the oversight and effectiveness of funded research programs.
Impact on the Public
Broadly, the bill intends to advance pediatric research, which carries the potential for significant public health benefits. By focusing resources on pediatric cancers and other diseases, it may facilitate new discoveries that could improve diagnostics, treatments, and outcomes for young patients. In the long term, this focus could play a role in reducing the burden of childhood diseases on families and healthcare systems.
However, without clear guidelines and accountability measures, the effectiveness of these investments may be compromised. If funds are not optimally allocated or if research efforts are duplicated, the anticipated benefits to public health might not be fully realized.
Impact on Specific Stakeholders
For stakeholders such as researchers and institutions focused on pediatric health, the bill provides a renewed opportunity to access funding and continue vital research initiatives. However, the lack of clarity regarding fund allocation and evaluation criteria may lead to uncertainties in planning and executing research projects.
Advocacy groups and families affected by pediatric diseases may view the bill positively, as it represents legislative attention and potential investment towards solutions. However, they may also be concerned about how effectively the bill is implemented given the highlighted ambiguities and potential for inefficiencies.
Overall, while the intent of the bill is commendable in its focus on necessary pediatric research, addressing its shortcomings could strengthen its potential impact and ensure that it delivers on its promises to the stakeholders involved.
Issues
The section on funding for the Pediatric Research Initiative (Section 2) lacks specific details on fund allocation, which might result in oversight issues. This is significant for financial accountability and transparency.
The change from 'Common Fund' to 'Division of Program Coordination, Planning, and Strategic Initiatives' in Section 2 is not clearly explained, potentially creating ambiguity regarding the impact on previously funded initiatives, which could have legal and procedural implications.
Section 3 of the bill does not specify mechanisms or criteria for determining duplication of research, possibly leading to inefficiencies in research funding. This is important for financial and operational effectiveness.
The lack of defined criteria or metrics for evaluating 'advancements made in pediatric research' in Section 4 could lead to subjective and potentially misleading reporting, affecting both financial oversight and public perception.
The amendment of several references in Section 2 without stating goals or expected outcomes for 2024 through 2028 leaves the impact of these changes on pediatric research unclear, which might affect stakeholders reliant on these initiatives.
Striking '10-year' from the heading and text in Section 2 might lead to confusion about the duration of funding, which is crucial for planning and operational stability for entities involved in the research.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
Section 1 provides the short title of the bill, which is officially named the "Gabriella Miller Kids First Research Act 2.0."
2. Funding for the Pediatric Research Initiative Read Opens in new tab
Summary AI
The section amends the Public Health Service Act to reallocate funding to the Division of Program Coordination, Planning, and Strategic Initiatives for pediatric research from 2024 to 2028, updating several legislative references and removing outdated terms related to the Common Fund.
3. Coordination of NIH funding for pediatric research Read Opens in new tab
Summary AI
The section highlights that Congress believes the Director of the National Institutes of Health should keep overseeing and coordinating research on pediatric diseases like cancer. It also amends a part of the Public Health Service Act to ensure that this pediatric research focuses on areas that don't duplicate existing National Institutes of Health research.
4. Report on progress and investments in pediatric research Read Opens in new tab
Summary AI
The Secretary of Health and Human Services is required to submit a report to Congress within five years of the law's enactment. This report should include details on pediatric research projects funded under a specific section of the Public Health Service Act and a summary of advancements made in pediatric research with those funds.